Prostate Cancer Screening and Detection: A Clinical Update
Description: Louis S. Liou, MD, PhD discusses clinical best practices and the guidelines offered by professional organizations related to the use of prostate-specific antigen (PSA) for prostate cancer screening as well as potential future biomarkers that can aid in prostate cancer diagnosis and/or prognosis.
Learning objectives — at the conclusion of this program participants will be able to:
• Communicate current guidelines, best practices, and recommendations regarding active surveillance for prostate cancer
• Discuss the clinical utility of PSA and its derivatives, as well as recent clinical studies regarding the appropriate utilization of PSA testing in various patient populations
• Describe new and emerging biomarkers that might help address the need for improved surveillance and diagnosis of disease aggressiveness